These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29750683)

  • 1. Hormone Therapy in Breast Cancer Survivors and Those at High Risk for Breast Cancer.
    Reid RL
    Clin Obstet Gynecol; 2018 Sep; 61(3):480-487. PubMed ID: 29750683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
    Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
    Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
    Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
    Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
    Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
    Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of systemic hormone therapy in BRCA mutation carriers.
    Domchek S; Kaunitz AM
    Menopause; 2016 Sep; 23(9):1026-7. PubMed ID: 27504919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer].
    Breda AS; Blaakær J
    Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
    Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].
    Pujol P; This P; Noruzinia M; Stoppa-Lyonnet D; Maudelonde T
    Bull Cancer; 2004; 91(7-8):583-91. PubMed ID: 15381448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
    Finch A; Evans G; Narod SA
    Womens Health (Lond); 2012 Sep; 8(5):543-55. PubMed ID: 22934728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
    Gronwald J; Tung N; Foulkes WD; Offit K; Gershoni R; Daly M; Kim-Sing C; Olsson H; Ainsworth P; Eisen A; Saal H; Friedman E; Olopade O; Osborne M; Weitzel J; Lynch H; Ghadirian P; Lubinski J; Sun P; Narod SA;
    Int J Cancer; 2006 May; 118(9):2281-4. PubMed ID: 16331614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone replacement therapy and beyond. The clinical challenge of menopausal symptoms in breast cancer survivors.
    Mortimer JE
    Geriatrics; 2002 Sep; 57(9):25-31. PubMed ID: 12271826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    Domchek SM
    JAMA; 2019 Jan; 321(1):27. PubMed ID: 30521006
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
    Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How medical choices influence quality of life of women carrying a BRCA mutation.
    Harmsen MG; Hermens RP; Prins JB; Hoogerbrugge N; de Hullu JA
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):555-68. PubMed ID: 26299336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience.
    Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA
    Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.